Sustained Virologic Response to Peginterferon $\alpha$-2a and Ribavirin in 335 Patients with Chronic Hepatitis C: A Tertiary Care Center Experience

Hamad Al Ashgar, Mohammed Q. Khan, Ahmed Helmy, Khalid Al Swat, Abdullah Al Shehri, Abdalla Al Kalbani, Musthafa Peedikayel, Khalid Al Kahtani, Mohammed Al Quaiz, Mohammed Rezeig, Ingvar Kagevi, Mohammed Al Fadda

ABSTRACT

Background/Aim: This retrospective study assessed the efficacy, safety, and the predictors of sustained viral response (SVR) to a 48-week-course of peginterferon $\alpha$-2a (Pegasys) and ribavirin combination therapy in 335 consecutive Saudi patients with chronic hepatitis C virus (HCV) infection. Materials and Methods: Clinical, biochemical, and virological parameters were collected at time 0 (pretreatment) and at 12, 24, 48, and 72 weeks posttreatment. The mean ± SD age was 49.1 ± 13.0 years; 229 (68.4%) were males, mean ± SD body mass index was 27.8 ± 7.4, 85 (25.4%) were diabetic, 25 (7.5%) had renal impairment, 136 (40.6%) had previously received interferon ± ribavirin therapy, and 247 (73.7%) underwent pretreatment liver biopsy. Patients with genotypes 1, 2 or 3, 4 and mixed genotype were 60 (22.15%), 30 (11.0%), 148 (54.4%), and 34 (12.5%), respectively. Results: Early viral response ($\geq 2$-log10 HCV-RNA decline 12 weeks posttreatment) was achieved in 253 (75.3%). Patients who completed 48 weeks of treatment were 292 (87.1%); of these, 121 (75.6%) achieved ETVR, 161 (55.1%) continued to have SVR and 60 (20.5%) had a viral relapse following end-of-treatment response, that is 48.1 and 17.9% of all patients (n = 335), respectively. Nonresponders (NR) were 71 (24.3%) patients and 43 (12.8%) were unable to complete treatment (due to side effects or loss to follow up). Compared to the relapers, patients with SVR were significantly younger ($P = 0.000$), nondiabetics ($P = 0.015$), had higher serum albumin ($P = 0.007$), had less pretreatment inflammatory grade ($P = 0.011$), infected with genotypes 2 or 3 ($P = 0.014$), and treatment-naïve patients ($P = 0.001$). However, in stepwise multivariate logistic regression analysis, only treatment naïve and low pretreatment inflammatory score were the independent predictors of SVR ($P = 0.005$ and $P = 0.018$, respectively). Conclusion: Combination therapy, if tolerated and completed, is effective in treating chronic HCV patients, especially those with no previous interferon therapy and lower pretreatment inflammatory grade.

Key Words: Antiviral therapy, hepatitis C genotype 4, predictors of viral response, viral relapse

Received 19.09.2007, Accepted 24.12.2007
The Saudi Journal of Gastroenterology 2008 14(2): 58-65

Chronic hepatitis C virus (HCV) infection affects approximately 300 million people worldwide and currently is the most frequent cause for liver transplantation in the United States and Europe.[1] Natural history studies suggest that up to 20% of chronic HCV patients develop liver cirrhosis after 20 years of infection. Moreover, the incidence of chronic liver failure is expected to increase over the next 10 years as a result of the “silent epidemic” of HCV infection.[2]

The recommended treatment for patients with HCV genotypes 1 and 4 is pegylated interferon plus ribavirin for 48 weeks.[3] Such treatment has yielded overall sustained viral response (SVR) rates of 54-63% in randomized controlled phase III clinical trials.[4,5] However, treatment responses are not uniform across all populations,[7] and are dependent on various viral and host factors. The majority of studies conducted worldwide have assessed the predictors of SVR in patients infected with HCV genotypes 1, 2, and 3, and showed that the factors independently associated with a favorable treatment result include serum HCV-RNA levels below 2 million copies/mL (800,000 IU/mL), body weight <75 kg, age <40 years, the absence of bridging fibrosis or cirrhosis in pretreatment liver biopsy, virus genotypes 2 or 3, and a favorable initial viral kinetic response.[4,6,8,10]

There are limited reports on HCV genotype 4, the most predominant genotype in the Middle East.[11] Most of the studies reporting on the treatment of chronic HCV from
the Middle East (mainly from Saudi Arabia, Egypt, Kuwait, and Qatar) are weakened by inclusion of small numbers of patients, use of conventional interferon, lack of sufficient data on HCV genotype and/or absence of data assessing the predictors of sustained response and/or viral relapse after end-of-treatment response. Other studies performed on genotype 4 patients outside the Middle East are subject to the same limitation.

Therefore, the primary objectives of this retrospective study conducted among 335 consecutive Saudi patients with chronic HCV infection were to (1) assess the overall efficacy of a 48-week course of peginterferon α-2a (Pegasys) and ribavirin combination therapy, (2) compare between patients who achieved SVR and those who relapsed after end-of-treatment viral response, and (3) define the independent predictors of SVR (persistently undetectable HCV RNA 6 months after cessation of treatment) in these patients.

**Materials and Methods**

**Patients**

A total of 335 consecutive patients with chronic HCV infection referred to King Faisal Specialist Hospital and Research Centre (KFSH and RC), Riyadh, Saudi Arabia, between February 2003 and November 2005 were included in this study. Baseline subject characteristics are shown in Table 1. This study was approved by both the Research Advisory Council and the Research Ethics Committee at KFSH and RC.

The accepted indications for starting treatment were the presence of detectable HCV RNA of any genotype, elevated serum alanine aminotransferase (ALT) >1.5-fold and histologically consistent with chronic hepatitis C using METAVIR scoring system. Patients were not excluded if they were hemophiliacs, had undergone transplantation, were on hemodialysis or had positive serology for hepatitis B or HIV viruses [Table 1]. Patients were excluded if they had overt active autoimmune or thyroid disorders, leukothrombocytopenia, hemolytic anemia, seizure disorders, decompensated cirrhosis, had focal lesion on abdominal ultrasonography or had elevated α-fetoprotein. None of the patients were treated and then excluded from the study. In other words, all those who started the treatment were included in the study analysis.

**Methods**

Baseline assessment included clinical history, physical examination, body mass index (BMI), as well as routine hematological, biochemical, serological, and virological tests including that of HCV genotype, HCV polymerase chain reaction (PCR).

After an initial assessment, patients were treated with pegylated interferon (40 kD; Pegasys®, F Hoffmann-La Roche, Basel, Switzerland) at a dose of 180 µg per week plus ribavirin (Copegus®, F Hoffmann-La Roche, Basel, Switzerland) at a dose of 1000-1200 mg daily as per body weight-1000 mg if ≤75 kg and 1200 mg if ≥75 kg-for 48 weeks. Clinical, biochemical, and viral parameters were collected pretreatment and at weeks 12, 24, 48, and 72 of follow up.

Pretreatment liver biopsy for pathological grading and staging was performed in 247 (73.7%) patients. The average period between the time of biopsy and start of treatment was 2.53 months. The hepatic necroinflammatory activity and stage of fibrosis in the biopsies were evaluated according to the METAVIR scoring system.

**HCV RNA assays**

Serum HCV RNA was extracted using an automated extraction system. HCV detection and quantification were performed using Abbott Real-Time M2000 RT-PCR assay, utilizing two sets of primers and probes, which target a conserved region of the 5' untranslated region of the genome and an internal control. This assay detects and quantifies HCV genotypes (1-6) with a detection limit that ranges from 30 to 100,000,000 IU/mL, where 1 IU/mL = 4 copies/mL. Prior to treatment, HCV genotype was assayed in 272 (81.2%) patients using INNO-LiPA HCV II (Innogenetics NV, Ghent, Belgium) as previously described.

**Definitions**

- The National Institute of Health guidelines state that a drop of ≥2-Log10 in serum HCV viral load is indicative

---

**Table 1: Baseline subject characteristics (n = 335)**

| Variable                          | Mean ± SD or n (%) |
|-----------------------------------|--------------------|
| Age (years)                       | 49.1 ± 13.0        |
| Sex (Male/Female)                 | 229 (68.4)/106 (31.6) |
| Body mass index (kg/m²)           | 27.8 ± 7.4         |
| Genotype*                         |                    |
| 1                                 | 60 (22.1)          |
| 2 or 3                            | 30 (11.0)          |
| 4                                 | 148 (45.4)         |
| Other and mixed                   | 34 (12.5)          |
| Diabetes (yes/no)                 | 85 (25.4%)/250 (74.6) |
| Renal impairment (yes/no)         | 25 (7.5)/310 (92.5) |
| Previous interferon therapy (yes/no) | 136 (40.6%)/199 (59.4) |
| Alcohol intake (yes/no)           | 9 (2.7%)/326 (97.3) |
| Previous organ transplant† (yes/no) | 28 (8.4%)/307 (91.6) |
| Positive autoantibodies (yes/no)  | 21 (6.3%)/314 (93.7) |
| Positive HBV or HIV (yes/no)      | 76 (22.7%)/259 (77.3) |
| Liver biopsy                      | 247 (73.7)         |

SD - Standard deviation; n - Number; HBV - Hepatitis B virus; HIV - Human immunodeficiency virus, *Genotype was determined in 272 (81.2%) patients, †Liver, kidney, or bone marrow transplant
Early viral response (EVR) was defined as ≥2-log10 drop in serum HCV viral load at 12 weeks after start of treatment.

End-of-treatment viral response (ETVR) was defined as undetectable serum HCV RNA at 48 weeks.

SVR was defined as persistently undetectable HCV RNA at 72 weeks (6 months after the end of course of treatment).

Nonresponse (NR) was defined as persistent positive HCV (PCR) after 48 weeks of treatment.

Data collection and statistical analysis

Data were collected initially using a specialized data collection form, then introduced into a Microsoft Excel worksheet and finally transferred to the statistical package for social sciences version 15.0 (SPSS; Chicago, IL, USA) for analysis. Means of continuous variables were compared using Student’s t-test, nonparametric tests (Wilcoxon’s and Mann-Whitney) or one-way analysis of variance (ANOVA) with Post-Hoc test (Turkey’s) as appropriate. The Chi-Square or Fisher’s exact tests were used to compare frequencies and proportions. Multivariate stepwise logistic regression analysis was performed to determine the independent predictors of sustained response. A P value of <0.05 was considered statistically significant. An intention-to-treat analysis was used. Patients who discontinued treatment either due to adverse effects or lost to follow up were not included in the analysis for NR, ETVR, and SVR.

RESULTS

HCV genotype

As shown in Table 1, HCV genotype was assayed in 272 patients (82.2%). Of these, 148 (54.4%) had genotype 4, while 60 (22.1%), 18 (6.6%), 12 (4.4%), 4 (1.5%), 2 (0.7%), and 28 (10.3%) had genotypes 1, 2, 3, 5, 6, and mixed genotype, respectively.

Table 2: Viral response rate in relation to the whole cohort and those who completed 48 weeks of treatment

| Group                  | Incomplete therapy | NR | ETVR | SVR | Relapse |
|------------------------|--------------------|----|------|-----|---------|
| Whole cohort (n = 335) | 43 (12.8)          | 71 (21.2) | 221 (65.9) | 161 (48.1) | 60 (17.9) |
| Completed treatment (n = 292) | -            | 71 (24.3) | 221 (75.6) | 161 (55.1) | 60 (20.5) |

Response rates in patients with genotypes 1 and 4 were similar. Also, they were similar to that seen in the entire cohort (n = 335) and were significantly worse than patients with genotype 2 or 3 (P < 0.01). P = 0.001 vs. pretreated patients, Figures in parentheses are in percentage

Biochemical response

Alanine aminotransferase level at baseline and at weeks 24, 48, and 72 in the sustained responders and those who developed virological relapse are shown in Figure 1. Both groups had similar ALT levels at all times except at week 72, in which those who relapsed after ETVR showed significantly higher ALT levels (P < 0.001).

Overall viral response

In the entire cohort (n = 335), EVR was achieved in 253 (75.3%). Nonresponse and incomplete treatment (due to side effects or loss to follow up) occurred in 71 (24.3%) and 43 (12.8%) patients, respectively. Patients who completed treatment were 292 (87.1%), of these, 161 (55.1%) achieved SVR and 60 (20.5%) developed virological relapse after end-of-treatment response, that is 48.1% and 17.9% of all patients, respectively [Table 2].

Viral response in relation to previous treatment

Viral response rates in the entire cohort, in those who completed treatment and based on whether the patients were previously treated with interferon are shown in Tables 2, 3, and Figure 2. Our results clearly show that the patients who are treatment-naïve have have significantly higher EVR (P = 0.036), higher SVR (P = 0.001), and lower relapse rate after ETVR (P < 0.001).

Viral response in relation to genotype

To address this issue, we selected the subgroup of patients in whom genotyping was done, having completed 48 weeks of treatment and achieving ETVR. These comprised 234
Table 4: Clinical characteristics of sustained responders versus relapsers after ETVR by univariate analysis

| Variable                  | Unit     | Patients with SVR (n = 161) | Relapsers after ETVR (n = 60) | P value |
|---------------------------|----------|-----------------------------|--------------------------------|---------|
| Age                       | years    | 46.1 ± 13.2                 | 53.2 ± 11.3                    | 0.000   |
| Sex M/F                   | n (%)    | 114 (70.8)/47 (29.2)        | 37 (61.7)/23 (38.3)            | NS      |
| Body mass index           | kg/m²    | 28.0 ± 7.6                  | 27.3 ± 5.5                     | NS      |
| Diabetes mellitus         | n (%)    | 27 (16.8)                   | 19 (31.7)                      | 0.015   |
| Renal failure             | n (%)    | 12 (7.5)                    | 3 (5.0)                        | NS      |
| Previous interferon       | n (%)    | 47 (29.2)                   | 32 (53.3)                      | 0.004   |
| Alcohol intake            | n (%)    | 6 (3.7)                     | 1 (1.7)                        | NS      |
| Organ transplant          | n (%)    | 13 (8.1)                    | 4 (6.7)                        | NS      |
| Hemophilia                | n (%)    | 12 (7.7)                    | 2 (3.4)                        | NS      |
| Ribavirin dose            | µg/day   | 923.9 ± 123.3               | 906.9 ± 155.4                  | NS      |
| Peginterferon dose        | µg/week  | 176.1 ± 16.3                | 180.0 ± 0.0                    | 0.062   |
| Ribavirin dose            | mg/kg/day| 12.8 ± 2.6                  | 12.7 ± 2.5                     | NS      |
| Peginterferon dose        | µg/kg/week| 2.5 ± 0.6                   | 2.7 ± 0.7                      | 0.077   |
| EVR*                      | n (%)    | 147 (94.8)                  | 52 (88.1)                      | NS      |

Data are expressed as mean ± SD or n (%) as appropriate; NS, not significant, i.e., P > 0.05; SD - Standard deviation; n - Number; M - Male; F - Female; BMI - Body mass index; *PCR at 12 weeks posttreatment was performed in 214 patients out of the 221 who completed the treatment, 155 in the SVR group and 59 in the relapsers after ETVR.

Figure 1: Mean ± SD serum alanine aminotransferase (ALT) levels in both patients with sustained virological response (SVR) and those who relapsed after end-of-treatment response (ETVR) at base line, 24, 48, and 72 weeks.

Figure 2: Percentage virological response in treatment naïve patients compared to those who were previously treated with interferon.

Predictors of sustained response
Clinical, laboratory, and pathological characteristics of patients who achieved SVR and those who developed virological relapse after ETVR are shown in Tables 4 and 5. Using the univariate analysis and compared to those who developed viral relapse after ETVR, patients with SVR were significantly younger (P = 0.000), mainly nondiabetics (P = 0.015), had higher levels of serum albumin (P = 0.007), were infected with genotype 2 or 3 (P = 0.014), had less pretreatment necro-inflammatory grade (P = 0.011), and were treatment-naïve (P = 0.001). Both groups were similar regarding pretreatment fibrosis stage and viral load [Table 5]. However, in stepwise multivariate logistic regression analysis (using the abovementioned six variables that were significant in the univariate analysis) only being treatment naïve was a predictor of sustained response.
naive and lower pretreatment necroinflammatory grade were the independent predictors of SVR ($P = 0.005$ and $P = 0.018$, respectively).

### Safety profile

A total of 327 side effects were encountered in 170 patients (50.7%) during follow up [Table 6]. The effects that were $\geq 5\%$ include fatigue, body aches, weight loss, depression, skin rash, anemia, leucopenia, and thrombocytopenia in 29 (8.7%), 17 (5.1%), 30 (9.0%), 20 (6.0%), 20 (6.0%), 63 (18.8%), 73 (21.8%), and 21 (6.3%) patients, respectively. Subcutaneous injections of erythropoietin and granulocyte-colony stimulating factor were used in 17 and 16 patients, respectively. That is, 27 and 21.9% of the patients who developed anemia ($n = 63$) and leucopenia ($n = 73$), respectively.

### DISCUSSION

This is the biggest cohort of chronic HCV-infected patients treated with the combination of pegylated interferon $\alpha$-2a and ribavirin to be reported from the Middle East, where infection with genotype 4 is predominant.[11] Our results confirm that patients infected with chronic HCV genotype 4, supported by the work of others,[13,15] can no longer be considered “difficult to treat.” With the use of the 48-week combination regimen and appropriate doses in 335 patients, SVR was achieved in 48.1% with intention-to-treat analysis and in 55.1% of 292 patients who tolerated and completed the full course of therapy. These results are similar to the responses achieved in previous studies that involved cohorts with predominantly HCV genotype 1 infection and less than the patients infected with HCV genotype 2 or 3.[28-30]

The current impression that the patients infected with HCV genotype 4 are difficult to treat and that they respond poorly

---

**Table 5: Laboratory and pathological characteristics of sustained responders vs. relapsers after ETVR by univariate analysis**

| Variable          | Unit     | Patients with SVR (n = 161) | Relapsers after ETVR (n = 60) | $P$ value |
|-------------------|----------|-----------------------------|-------------------------------|-----------|
| WBC               | $\times 10^9$/L | 6.3 ± 2.2                  | 6.0 ± 2.4                     | NS        |
| Hemoglobin        | g/L      | 143.9 ± 20.2                | 139.1 ± 18.2                  | NS        |
| Platelets         | $\times 10^9$/L | 245.0 ± 94.8               | 232.9 ± 85.9                  | NS        |
| INR               |          | 0.99 ± 0.13                 | 1.00 ± 0.30                   | NS        |
| Bilirubin         | $\mu$mol/L | 23.2 ± 125.6               | 13.8 ± 12.3                   | NS        |
| ALT               | IU/L     | 92.4 ± 83.5                 | 92.7 ± 62.4                   | NS        |
| AST               | IU/L     | 65.7 ± 67.3                 | 78.2 ± 53.0                   | NS        |
| HCV viral load    | copy/mL  | 5.6 ± 8.0 $E + 06$         | 7.1 ± 9.5 $E + 06$            | NS        |
| GGT               | IU/L     | 90.4 ± 66.1                 | 122.5 ± 95.9                  | NS        |
| Albumin           | g/L      | 40.4 ± 4.2                  | 38.7 ± 4.0                    | 0.007     |
| Creatinine        | $\mu$mol/L | 112.7 ± 143.3              | 99.7 ± 111.5                  | NS        |
| Cholesterol       | $\mu$mol/L | 3.6 ± 1.4                   | 3.5 ± 1.1                     | NS        |
| AFP               | IU/L     | 8.1 ± 17.2                  | 11.2 ± 26.2                   | NS        |
| Genotype 4        | n (%)    | 66 (50.0)$^*$               | 30 (57.7)$^*$                 | NS        |
| Genotype 2 or 3   | n (%)    | 18 (19.4)$^|$               | 2 (6.3)$^|$                   | 0.059     |
| Inflammatory grade$^|$ | n (%) | 103 (88.0)                  | 36 (72.0)                     |           |
| 0-2               | n (%)    | 14 (12.0)                   | 14 (28.0)                     | 0.11      |
| 3-4               | n (%)    | 89 (76.1)                   | 35 (70.0)                     |           |
| Fibrosis stage$^|$ | n (%)    | 28 (23.9)                   | 15 (30.0)                     | NS        |

Data are expressed as mean ± SD; NS, not significant, i.e., $P > 0.05$. SD, standard deviation; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, $\gamma$-glutamyl transferase; AFP, $\alpha$-fetoprotein. *Genotyping was done in 132 patients only; †Genotyping was done in 52 patients only; $^|$Liver biopsy was done in 167 patients out of the 292 who completed the treatment.

---

**Figure 3:** Percentage viral responses in relation to genotype. NR - Nonresponse. SVR - Sustained viral response.

This is the biggest cohort of chronic HCV-infected patients treated with the combination of pegylated interferon $\alpha$-2a and ribavirin to be reported from the Middle East, where infection with genotype 4 is predominant.[11] Our results confirm that patients infected with chronic HCV genotype 4, supported by the work of others,[13,15] can no longer be considered “difficult to treat.” With the use of the 48-week combination regimen and appropriate doses in 335 patients, SVR was achieved in 48.1% with intention-to-treat analysis and in 55.1% of 292 patients who tolerated and completed the full course of therapy. These results are similar to the responses achieved in previous studies that involved cohorts with predominantly HCV genotype 1 infection and less than the patients infected with HCV genotype 2 or 3.[28-30] The current impression that the patients infected with HCV genotype 4 are difficult to treat and that they respond poorly...
to interferon therapy was made based on earlier studies where conventional interferon-α was used alone. On the other hand, studies that used pegylated interferon combined with ribavirin on genotype 4 patients showed better results than ours, possibly due to the heterogeneity of our patients and the inclusion of many patients with co-morbidities, associated HBV or HIV infections organ transplant and failed response to previous interferon-based therapy. The SVR was observed in 55.5 and 69% of patients who received treatment for 48 weeks. These studies have the strength of being prospective and randomized, and only including patients with genotype 4. However, out of a total of 180 and 287 patients, only 40 and 91 patients, respectively, were treated for 48 weeks in these two studies. One study assessed the predictors of SVR. Similarly, SVR was observed in 43.8% of patients after 48 weeks of treatment and only 28 patients had genotype 4. Other studies showed a much lower SVR of 33.3%, a difference that might be related to host- or viral-related factors or to the small number of patients included (only 30 patients). A total of 71 (24.3%) patients were classified as NR after 48 weeks of therapy and their treatment was discontinued. However, due to the tertiary nature of our hospital and the inclusion of many cases in whom interferon therapy had failed before, cases with organ transplantation and on immunosuppressive therapy, cases co-infected with HIV and/or HBV, cases infected with mixed HCV genotypes and the inclusion of a small number of cases with genotype 2 or 3 (n = 30), this rate of nonresponse is acceptable.

Fibrosis stage by pretreatment liver biopsy was not found to be statistically different between sustained responders and those who developed viral relapse after ETVR. This is contrary to what was previously reported by other studies in both genotypes 1 and 4.”

Baseline HCV viral load was not found to be a predictor of SVR in our study. It is well known that viral load fluctuates and a single reading of HCV quantification may not reflect the actual viral load at the time of treatment, especially if it was assessed at varying intervals from the date of start of treatment. It has also been reported that the differences in interferon response could be secondary to either difference in the viral virulence and/or replication rate among different HCV genotypes and not the absolute viral load.

The safety profile of the combination therapy of pegylated-interferon α-2a and ribavirin used in the present study is comparable to what was previously described in the literature. Indeed, only 43 (12.8%) patients did not complete their course of treatment in our study due to the development of side effects, lost follow-up and/or transfer to liver transplantation or development of contraindication.

The SVR (34.6%) in our patients who previously received interferon therapy is better than that concluded in many studies for both genotypes 1 and 4. The mechanism(s) underlying this higher response is due to the inclusion of majority of patients who received standard interferon alone (and not combination therapy). The overall low SVR in the previously treated patients may be related to the development of an intrinsic or immunological resistance to the direct antiviral effect of interferon. Mathew et al. reported that the response rates were almost double in patients who were previously treated with interferon monotherapy (24%) compared to those previously treated with combination therapy (12-16%), but without any statistical difference; these values were 28 and 12% in the HALT study. Interestingly, interferon-inducible protein 10 kDa (IP-10), which is a chemokine produced by hepatocytes and targets T-lymphocytes, natural killer cells and monocytes was recently identified. Elevated serum levels of IP-10 before initiation of therapeutic intervention for HCV infection were reported in patients not achieving SVR.

A recent study confirmed that pretreatment IP-10 levels predict SVR in patients infected with HCV genotype 1, even in those with higher BMI and viral load. Thus, assessment of pretreatment IP-10 may help in identifying patients for whom current therapy is beneficial. This protein needs to be tested in patients infected with HCV genotype 4, especially those in whom interferon therapy had failed previously.

---

**Table 6: Frequency of main side effects encountered during therapy**

| Side effect                                      | Frequency |
|--------------------------------------------------|-----------|
| Fatigue                                          | 29 (8.7)  |
| Body aches (myalgia, arthralgia, and headache)   | 17 (5.1)  |
| Weight loss                                      | 30 (9.0)  |
| Itching                                          | 15 (4.5)  |
| Skin rash                                        | 20 (6.0)  |
| Depression                                       | 20 (6.0)  |
| Worsening liver function                         | 3 (0.9)   |
| Thyroid dysfunction*                             | 12 (3.6)  |
| Anemia                                           | 63 (18.8) |
| Leucopenia                                       | 73 (21.8) |
| Thrombocytopenia                                 | 21 (6.3)  |
| Fever                                            | 8 (3.4)   |
| Others†                                          | 13 (3.9)  |

Data are expressed as n(%); *Thyroid dysfunction in the form hypo- or hyperthyroidism; †Others include anorexia (n = 1), nausea (n = 1), cough (n = 5), myopathy (n = 2), neuropathy (n = 2), and nephrosis (n = 1).
The potential limitations of the current study can be summarized in the following points: (1) Posttreatment biopsy was not performed as the main objective of the study was to assess the rate of SVR, which was assayed using serum HCV PCR, relying on the well-established information in the literature that proved stabilization and/or regression in hepatic fibrosis stage in response to treatment, especially if it is associated with viral clearance.\textsuperscript{[17,39]} In addition, assessing the impact of therapy on liver histopathology was beyond the scope of this study. (2) Due to the retrospective nature of the present study, baseline liver biopsy and HCV genotyping were performed in the majority, but not all cases. It is clear that if these two important baseline parameters were performed in all patients, better assessment of their role as predictors of SVR can be done. However, the fact that the percentage of patients who have achieved SVR in the present study is similar to what is already reported in other studies makes it less likely to substantially affect the results.

In conclusion, combination therapy, if tolerated and completed, is effective in treating chronic HCV patients, especially in those with no previous interferon therapy and with low pretreatment inflammatory grade. Persistent efforts and support measures need to be implemented, possibly through a specialized dedicated clinic, to improve patient compliance with follow-up, adherence to therapy, tolerance to treatment, early detection, and subsequent treatment of complications, if any. Further studies addressing the possible underlying mechanism(s) responsible for SVR, including the pretreatment assessment of IP10 levels, are warranted.

REFERENCES

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41-52.
2. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002;36:35-46.
3. NIH Consensus Statement on Management of Hepatitis C: 2002 NIH Consensus Sci Statement 2002;19:1-46.
4. Freid MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçalves FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
5. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diogo M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;130:231-64.
6. Tsubota A, Arase Y, Someya T, Suzuki Y, Suzuki F, Saitho S, et al. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol 2005;75:27-34.
7. Manss MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Rein Udorner R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958-65.
8. Ferenci P. Predicting the therapeutic response in patients with chronic hepatitis C: The role of viral kinetic studies. J Antimicrob Chemother 2004;53:15-8.
9. Shobokshi OA, Serebour FE, Skakni L, Al-Saffy YH, Ahdal MN. Hepatitis C genotypes and subtypes in Saudi Arabia. J Med Virol 1999;58:44-8.
10. Derbala MF, Al Kaabi SR, El Dweik NZ, Pasic F, Butt MT, Yakob R, et al. Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: Impact of bilharziasis and fibrosis stage. World J Gastroenterol 2006;12:5692-8.
11. El-Zayadi AR, Attia M, Barakat EM, Badran HM, Hamdy H, El-Tawil A, et al. Response of hepatitis C genotype-4 naive patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: A non-randomized controlled study. Am J Gastroenterol 2005;100:2447-52.
12. Legrand-Abравanel F, Nicot F, Boulestin A, Sandres-Saune K, Vinel JP, Airic L, et al. Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. J Med Virol 2005;77:66-9.
13. Kamal SM, El Tawil AA, Nakano T, He Q, Rasenack J, Hakam SA, et al. Peginterferon (alfa)-2b and ribavirin therapy in chronic hepatitis C genotype 4: Impact of treatment duration and viral kinetics on sustained virological response. Gut 2005;54:858-66.
14. al-Faleh FZ, Sheikh F, al-Karawi M, al-Mofleh IA, al-Rashed RS, Ayoola A, et al. Treatment of chronic hepatitis C genotype 4 with alpha-interferon in Saudi Arabia: A multicenter study. Hepatogastroenterology 1998;45:488-91.
15. Kosh A, Madda JP, Marcellin P, Martinot M. Treatment of hepatitis C virus genotype 4-related cirrhosis: Ribavirin and interferon combination compared with interferon alone. J Clin Gastroenterol 2002;35:82-5.
16. al-Zayadi A, Selim O, Haddad S, Simmonds P, Hamdy H, Badran HM, et al. Combination treatment of interferon alpha-2b and ribavirin in comparison to interferon monotherapy in treatment of chronic hepatitis C genotype 4 patients. Ital J Gastroenterol Hepatol 1999;31:472-5.
17. al-Faleh FZ, Al-Jumah A, Reizejg M, Al-Kanawi M, Al-Otaibi M, Haladla M, et al. Treatment of chronic hepatitis C genotype IV with interferon-ribavirin combination in Saudi Arabia: A multicenter study. J Viral Hepatitis 2000;7:287-91.
18. al-Faleh FZ, Hadad Q, Khuuro MS, Aljumah A, Algamedi A, Alshagar H, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver Int 2004;24:568-74.
19. Hasan F, Asker H, Al-Khaldi J, Siddique I, Al-Ajmi M, Owaid S, et al. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol 2004;99:1733-7.
20. Al-Taifi I, Handoo FA, Al-Jumah A, Al-Nasser M. Chronic hepatitis C: Genotypes and response to anti-viral therapy among Saudi patients. Saudi Med J 2004;25:1935-8.
21. Bruno S, Crosignani A, Pinzello GB. Hepatitis C virus genotype 4 and response to combination therapy with interferon-alpha2b plus ribavirin. Ann Intern Med 2000;133:922-3.
22. Zylberberg H, Chaix ML, Brechet C. Infection with hepatitis C virus genotype 4 is associated with a poor response to interferon-alpha. Ann Intern Med 2000;132:645-6.
23. Sherman M, Marinos G, Sedara F. Infection with hepatitis C virus genotype 4 is associated with a poor response to interferon-alpha. Ann Intern Med 2001;135:927-8.
26. The METAVIR cooperative group. Inter-and intra-observer variation in the assessment of liver biopsy of chronic hepatitis C. Hepatology 1994;20:15-20.

27. Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborghet B, Van Heuverswyn H, et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993;74:1093-102.

28. Trepo C. Genotype and viral load as prognostic indicators in the treatment of hepatitis C. J Viral Hepat 2000;7:250-7.

29. Hu KQ, Vierling JM, Redeker AG. Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. J Viral Hepat 2001;8:1-18.

30. Khuroo MS, Khuroo MS, Dahab ST. Meta-analysis: A randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. Aliment Pharmacol Ther 2004;20:931-8.

31. Arif A, Levine RA, Sanderson SO, Bank L, Velu RF, Shah A, et al. Regression of fibrosis in chronic hepatitis C after therapy with interferon and ribavirin. Dig Dis Sci 2003;48:1425-30.

32. Metwally MA, Zein CO, Zein NN. Regression of hepatic fibrosis and cirrhosis in patients with chronic hepatitis C treated with interferon-based therapy. Gastroenterology 2003;124:1561.

33. Dufour JF, DeLellis R, Kaplan MM. Regression of hepatic fibrosis and cirrhosis in patients with chronic hepatitis C treated with interferon-based therapy. J Viral Hepat 2000;30:74-81.

34. Simin M, Brok J, Stimac D, Gluud C, Gluud LL. Cochrane systematic review: Pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C. Aliment Pharmacol Ther 2007;25:1153-62.

35. Mathew A, Peiffer LP, Rhoades K, McGarrity T. Sustained viral response to pegylated interferon alpha-2b and ribavirin in chronic hepatitis C refractory to prior treatment. Dig Dis Sci 2006;51:1956-61.

36. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004;126:1015-23.

37. Hua LL, Lee SC. Distinct patterns of stimulus-inducible chemokine mRNA accumulation in human fetal astrocytes and microglia. Glia 2000;30:74-81.

38. Harvey CE, Post JJ, Palladinetti P, Freeman AJ, Ffrench RA, Kumar RK, et al. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukoc Biol 2003;74:360-9.

39. Butera D, Marukian S, Iwamaye AE, Chambers TJ, Di Bisceglie AM, et al. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood 2005;106:1175-82.

40. Diago M, Castellano G, Garcia-Samaniego J, Perez C, Fernandez I, Romero M, et al. Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C. Gut 2006;55:374-9.

41. Lagging M, Romero Al, Westin J, Norkrans G, Dhillon AP, Pawlotsky J, et al. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology 2006;44:1617-25.

Source of Support: Nil, Conflict of Interest: None declared.

Author Help: Online Submission of the Manuscripts

Articles can be submitted online from http://www.journalonweb.com. For online submission articles should be prepared in two files (first page file and article file). Images should be submitted separately.

1) First Page File:
Prepare the title page, covering letter, acknowledgement, etc., using a word processor program. All information which can reveal your identity should be here. Use text/rtf/doc/pdf files. Do not zip the files.

2) Article file:
The main text of the article, beginning from Abstract till References (including tables) should be in this file. Do not include any information (such as acknowledgement, your names in page headers, etc.) in this file. Use text/rtf/doc/pdf files. Do not zip the files. Limit the file size to 400 kb. Do not incorporate images in the file. If file size is large, graphs can be submitted as images separately without incorporating them in the article file to reduce the size of the file.

3) Images:
Submit good quality colour images. Each image should be less than 400 kb in size. Size of the image can be reduced by decreasing the actual height and width of the images (keep up to about 4 inches) or by reducing the quality of image. All image formats (jpeg, tiff, gif, bmp, png, eps, etc.) are acceptable; jpeg is most suitable. The image quality should be good enough to judge the scientific value of the image. Always retain a good quality, high resolution image for print purpose. This high resolution image should be sent to the editorial office at the time of sending a revised article.

4) Legends:
Legends for the figures/images should be included at the end of the article file.